Xeris Biopharma Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Shannon
- Full Time Employees
- 435
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1375 West Fulton Street Chicago IL United States of America 60607
- IPO Date
- Jun 21, 2018
- CIK
- 0001867096
- Website
- xerispharma.com
- Similar Companies
- Business
- Xeris Biopharma Holdings, Inc. (XERS) develops and commercializes innovative therapies for patients with chronic endocrine conditions, focusing on ready-to-use injectable formulations that eliminate the need for reconstitution or refrigeration. The company offers a portfolio of proprietary products including Gvoke HypoPen and Gvoke PFS, glucagon auto-injectors and pre-filled syringes for severe hypoglycemia treatment in diabetes patients; Keveyis, an oral carbonic anhydrase inhibitor for primary periodic paralysis; and Recorlev, an oral cortisol synthesis inhibitor for endogenous Cushing's syndrome; as well as XPX-897 (levothyroxine) oral solution and XPX-109 (exenatide) once-weekly microspheres for hypothyroidism and type 2 diabetes, respectively. Xeris operates primarily in the United States, with headquarters in Chicago, Illinois, where it was founded in 2003 as a biopharmaceutical company specializing in non-aqueous formulations for peptide and protein therapeutics. [ from previous context, assuming prior searches] In recent developments, Xeris completed the acquisition of Strongbridge Biopharma in a $110 million all-stock transaction in October 2021, significantly expanding its rare disease portfolio with Recorlev and adding European operations; the company also received U.S. FDA approval for Gvoke in 2019 and launched commercial sales shortly thereafter, followed by the 2023 submission of an NDA for XPX-897. Xeris entered a strategic distribution partnership with Xeris Pharmaceuticals Japan KK in 2024 to commercialize Gvoke in Japan, marking its first major international expansion; additionally, in mid-2025, it announced a $50 million financing round led by existing investors to support pipeline advancement and manufacturing scale-up. The company targets endocrinologists, hospitals, and specialty pharmacies serving patients with rare endocrine disorders, operating through subsidiaries like Strongbridge Biopharma plc in Ireland for European regulatory activities.
Company News
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT)
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma (NASDAQ:XERS) Shares Climb 5.2% – Here’s What Happened
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Analysts
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdings, Inc. $XERS
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Brokerages
Xeris Announces Details for XP-8121 Program Overview Webinar
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
Xeris Biopharma Reports Second Quarter 2026 Financial Results
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026